Source link : https://newshealth.biz/health-news/immunotherapy-regimen-approved-for-recurrent-ovarian-cancer/
(MedPage Today) — The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday. Approval stipulates use of the combination, with or without bevacizumab, in adults… Source link : https://www.medpagetoday.com/hematologyoncology/ovariancancer/119831 Author : Publish date : 2026-02-10 22:32:00 Copyright for syndicated content belongs to the linked Source.
The post Immunotherapy Regimen Approved for Recurrent Ovarian Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-02-10 22:32:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8